CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 420 enrolled
Drug / intervention
Comparator: Placebo +8 moredrug
Likely dose
MK0974 25–600 mg orally, single dose (dose-finding study); active comparator Rizatriptan 10 mg orally, single doseAI-extracted
Key inclusion· 2
  • ✓At least 1 year history of migraine with or without aura
  • ✓General good health based on screening assessment
Key exclusion· 5
  • ✕Pregnancy or breast-feeding, or plans to conceive during study
  • ✕Heart disease, uncontrolled hypertension, uncontrolled diabetes, or other significant disease
  • ✕Major depression, other pain syndromes, psychiatric conditions, dementia, or significant neurological disorders (other than migraine)
  • ✕History of gastric or small intestinal surgery or malabsorption disease

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00246337
NCT00246337Phase 2Completed
CompareCT.gov

A Multicenter, Double-Blind, Placebo and Active-Controlled, Dose-Finding Study of MK0974 in the Treatment of Acute Migraine

Merck Sharp & Dohme LLC·interventional·Posted Oct 31, 2005·Updated Nov 2, 2015

In Brief

A Phase 2 clinical trial evaluating Comparator: Placebo, MK0974, and 1 other intervention for Migraine. Completed, enrolled 420 participants.

Detailed Summary

The purpose of this study is to investigate the efficacy and safety of an MK 0974 for migraine headache and to identify an appropriate dose range for further study.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMigraine
Countries--
Collaborators--

Timeline

Phase 2CompletedFinished
2006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedOct 31, 2005
Enrollment StartNov 1, 2005
Primary CompletionMay 1, 2006
TodayJul 2, 2026
Enrollment to primary: 6 monthsPosted 20.7 years ago

Interventions

Comparator: Placebodrug

Placebo to match assigned treatment arm; one orally-administered dose

MK0974drug

MK0974 25 mg; one orally-administered dose

MK0974drug

MK0974 50 mg; one orally-administered dose

MK0974drug

MK0974 100 mg; one orally-administered dose

MK0974drug

MK0974 200 mg; one orally-administered dose

MK0974drug

MK0974 300 mg; one orally-administered dose

MK0974drug

MK0974 400 mg; one orally-administered dose

MK0974drug

MK0974 600 mg; one orally-administered dose

Rizatriptandrug

Rizatriptan 10 mg; one orally-administered dose